Prakt. lékáren. 2019; 15(2): 82-84 | DOI: 10.36290/lek.2019.014

Current trends in the hormone replacement therapy

Pavel Trávník
REPROMEDA, s. r. o., Brno
Institut postgraduálního vzdělávání ve zdravotnictví, Praha

In past decades the hormonal replacement therapy was often the subject of discussion. In the last several years the opinion
concerning the suitability, indications, and contraindications of this therapy stabilizes. In the paper the conclusions of recent
publications and statements of professional societies are given.

Keywords: hormone replacement therapy, HRT, menopausal hormone therapy, MHT, estradiol, progesterone

Published: June 20, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Trávník P. Current trends in the hormone replacement therapy. Praktické lékárenství. 2019;15(2):82-84. doi: 10.36290/lek.2019.014.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Trávník P. Farmakologická podpora časné gravidity. Prakt. Lekáren. 2012; 8(6): 259-261.
    2. Fait T. Nové pohledy na hormonální substituční terapii. Vnitř Lék 2014; 60(11): 942-947. Go to PubMed...
    3. Živný J. Stárnutí ženy a hormonální substituční terapie. Interní Med. 2004; 6(8): 403-409.
    4. Lobo RA. Hormone-replacement therapy: current thinking. Nat Rev Endocrinol. 2017 Apr; 13(4): 220-231. Go to original source... Go to PubMed...
    5. Langer RD. The evidence base for HRT: what can we believe? Climacteric. 2017 Apr; 20(2): 91-96. Go to original source... Go to PubMed...
    6. Hashim D, Sartori S, La Vecchia C, Serraino D, Dal Maso L, Negri E, Smith E, Levi F, Boccia S, Cadoni G, Luu HN, Lee YCA, Hashibe M, Boffetta P. Hormone factors play a favorable role in female head and neck cancer risk. Cancer Medicine 2017; 6(8): 1998-2007 Go to original source... Go to PubMed...
    7. MacGregor EA. Migraine, menopause and hormone replacement therapy. Post Reprod Health. 2018 Mar; 24(1): 11-18. Go to original source... Go to PubMed...
    8. Simin J, Tamimi R, Lagergren J, Adami HO, Brusselaers N. Menopausal hormone therapy and cancer risk: An overestimated risk? Eur J Cancer. 2017 Oct; 84: 60-68. Go to original source... Go to PubMed...
    9. Brusselaers N, Tamimi RM, Konings P, Rosner B, Adami HO, Lagergren J. Different menopausal hormone regimens and risk of breast cancer. Ann Oncol. 2018 Aug 1; 29(8): 1771-1776. Go to original source... Go to PubMed...
    10. L'Hermite M. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ? progesterone) are optimal. Climacteric. 2017 Aug; 20(4): 331-338. Go to original source... Go to PubMed...
    11. Gompel A. Micronized progesterone and its impact on the endometrium and breast vs. progestogens. Climacteric. 2012 Apr;15 Suppl 1: 18-25. Go to original source... Go to PubMed...
    12. Lambrinoudaki I. Progestogens in postmenopausal hormone therapy and the risk of breast cancer. Maturitas. 2014 Apr;77(4): 311-317. Go to original source... Go to PubMed...
    13. Wang S, Wang Y, Xu J, Chen Y. Is the oral contraceptive or hormone replacement therapy a risk factor for cholelithiasis? Medicine 2017: 96: 14. Go to original source... Go to PubMed...
    14. Santen RJ. Vaginal administration of estradiol: effects of dose, preparation and timing on plasma estradiol levels. Climacteric. 2015 Apr; 18(2): 121-134. Go to original source... Go to PubMed...
    15. Rhoda HC, Goodman NF. American Association of Clinical Endocrinologists and American College of Endocrinology position statement on menopause-2017 update. Endocrine Practice: July 2017, Vol. 23, No. 7, pp. 869-880. Go to PubMed...
    16. L'Esperance S, Frenette S, Dionne A, Dionne JY. Pharmacological and non-hormonal treatment of hot flashes in breast cancer survivors: CEPO review and recommendations. Support Care Cancer 2013; 21: 1461-1474. Go to original source... Go to PubMed...
    17. Busby J, Murray L, Mills K, Zhang SD, Liberante F, Cardwell CR. A combined connectivity mapping and pharmacoepidemiology approach to identify existing medications with breast cancer causing or preventing properties. Pharmacoepidemiol Drug Saf. 2018 Jan; 27(1): 78-86. Go to original source... Go to PubMed...

    Return to the content


    Pharmacy for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.